Quintiles Transnational Holdings Inc (Q) reported quarterly earnings results on Wednesday, Jul-27-2016. The company said it had a profit of $0.93 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $0.90. The company posted revenue of $1167.10 million in the period, compared to analysts expectations of $1150.61 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Quintiles Transnational Holdings Inc was Upgraded by Avondale to ” Mkt Outperform” on Jul 12, 2016. Quintiles Transnational Holdings Inc was Downgraded by Wells Fargo to ” Market Perform” on May 12, 2016. Shares were Downgraded by Robert W. Baird on May 4, 2016 to ” Neutral” and Lowered the Price Target to $ 74 from a previous price target of $76 .
Quintiles Transnational Holdings Inc opened for trading at $75.55 and hit $78.3 on the upside on Thursday, eventually ending the session at $77.92, with a gain of 3.89% or 2.92 points. The heightened volatility saw the trading volume jump to 21,69,710 shares. Company has a market cap of $9,325 M.
In a different news, on Jun 10, 2016, Kevin K Gordon (EVP and COO) sold 24,000 shares at $66.41 per share price. According to the SEC, on May 16, 2016, Annie H. Lo (director) purchased 502 shares at $64.80 per share price. On Sep 3, 2015, Charles Edward Williams (Sr VP and Controller) sold 5,000 shares at $72.43 per share price, according to the Form-4 filing with the securities and exchange commission.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.